Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...
Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果